SEC Form 4 · accession 0001940272-26-000010
InMed Pharmaceuticals Inc. · INM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 7:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001728328
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Jul 15, 2026 | P | 1,000 | $1.555 | A | 801,000 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
- F2For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.